Efficacy News and Research

RSS

SARS-CoV-2 Omicron variant's infectivity, vaccine breakthrough, and antibody resistance

A recent study uses an artificial intelligence model to investigate Omicron's mutations and its infectivity, vaccine escape capability, and susceptibility to monoclonal antibodies.

10 Jan 2022

SARS-CoV-2 omicron variant predicted to cause fewer deaths in Florida

Scientists have predicted a lower number of infections and deaths caused by the omicron variant of severe acute respiratory syndrome coronavirus 2 in Florida

10 Jan 2022

Researchers discover a potential depression biomarker and why it affects women and men differently

A team of Université Laval scientists may have discovered why severe depression affects women and men differently, according to a study published today in Nature Communications.

10 Jan 2022

SARS-CoV-2 shown to spread through cell-to-cell transmission

A new study investigated SARS-CoV-2 cell-to-cell transmission in the context of cell-free infection and compared it to SARS-CoV.

10 Jan 2022

Declining effectiveness of the BNT162b2 vaccine in adolescents infected with COVID-19

Researchers have conducted a retrospective matched case-control study to determine the protection period conferred by the BNT162b2 vaccine on adolescents aged 12 to 16.

10 Jan 2022

SARS-CoV-2 Delta sublineage AY.4.2 shows no increase in cell entry or antibody evasion

Researchers from Germany, in their recent study published in the journal Cellular & Molecular Immunology, have evaluated the mutations in the S protein of one such SARS-CoV-2 strain, a Delta sublineage AY.4.2, which is currently expanding in the UK, and have found that it neither contains any potential for increased cell entry nor antibody escape.

10 Jan 2022

NYBC discovers novel small-molecule pancoronavirus fusion inhibitors

New York Blood Center has published a study that reports the discovery of highly potent small molecules with the ability to inhibit COVID-19 in infected individuals.

9 Jan 2022

History of SARS-CoV-2 infection affects longitudinal responses to BNT162b2 vaccine

In a recently published article in the journal Cell Reports, scientists have demonstrated that individuals with or without a history of coronavirus disease 2019 (COVID-19) exhibit differential humoral and cellular immune responses 14 days after receiving mRNA-based COVID-19 vaccine developed by Pfizer/BioNTech. However, at a later time point, the responses become comparable between the two groups.

9 Jan 2022

Engineered small extracellular vesicles for the neutralization of SARS-CoV-2

Characterizing these engineered sEVs, the researchers demonstrated that the soluble angiotensin-converting enzyme 2 (sACE-2) loaded sEV successfully binds and thus inhibits the entry of wild-type SARS-CoV-2 as well as its variants, protecting against SARS-CoV-2 infection. They also demonstrated the therapeutic efficacy of these engineered sEVs in vivo.

9 Jan 2022

Bolstering current therapeutic antibody treatments to help fight Omicron infections

Researchers test the neutralizing action of a panel of eight therapeutic monoclonal antibodies against the SARS-CoV-2 Omicron (B.1.1.529) variant.

9 Jan 2022

Lab engineered human A549 lung cell model conducive for investigating SARS-CoV-2 antivirals

Researchers developed a human A549 lung epithelial cell-based model to probe SARS-CoV-2 replication.

9 Jan 2022

Slight pH adjustment may turn a metabolic inhibiting drug into promising COVID-19 treatment

Mechanical engineering and materials science professor David Needham has shown that a slight increase in solution pH might be all it takes to turn a metabolic inhibiting drug, traditionally used to treat gut parasites, into a promising prophylactic/preventative nasal spray and early treatment throat spray for COVID-19.

7 Jan 2022

Engineering hairy cellulose nanocrystals to capture chemotherapy drugs

Millions of people around the globe are affected by cancer each year; more than 39% of men and women are diagnosed with cancer during their lifetime.

7 Jan 2022

NEJM article distills available data into a compendium about rapid diagnostic tests for COVID-19

A clinical practice article in the New England Journal of Medicine distills available data and clinical experience into a compendium about rapid diagnostic tests for SARS-CoV-2, the virus that causes COVID-19.

7 Jan 2022

N95 respirators can be safely re-used up to 25 times after VHP decontamination

N95 respirators are commonly used in hospitals worldwide to protect healthcare personnel from infectious pathogens. During the COVID-19 pandemic, healthcare facilities have experienced shortages of the respirators, forcing personnel to re-use them or resort to less protective masking alternatives.

7 Jan 2022

Omicron variant found to be much less sensitive to neutralizing antibodies than Delta

The Omicron variant was detected for the first time in South Africa in November 2021 and has since spread to many countries.

7 Jan 2022

Researchers isolate Omicron variant, leveling the path to vaccine development and vaccine efficacy studies

Researchers from India have now successfully grown and isolated the Omicron variant from hamsters in vivo with further culturing in the Vero CCL-81 cells in vitro, in a step forward towards testing the effectiveness of existing SARS-CoV-2 vaccines and generation of new Omicron appropriate vaccines.

7 Jan 2022

Efficacy News and Research

SARS-CoV-2 Omicron variant's infectivity, vaccine breakthrough, and antibody resistance

SARS-CoV-2 omicron variant predicted to cause fewer deaths in Florida

Researchers discover a potential depression biomarker and why it affects women and men differently

SARS-CoV-2 shown to spread through cell-to-cell transmission

Declining effectiveness of the BNT162b2 vaccine in adolescents infected with COVID-19

SARS-CoV-2 Delta sublineage AY.4.2 shows no increase in cell entry or antibody evasion

NYBC discovers novel small-molecule pancoronavirus fusion inhibitors

History of SARS-CoV-2 infection affects longitudinal responses to BNT162b2 vaccine

Engineered small extracellular vesicles for the neutralization of SARS-CoV-2

Bolstering current therapeutic antibody treatments to help fight Omicron infections

Lab engineered human A549 lung cell model conducive for investigating SARS-CoV-2 antivirals

Slight pH adjustment may turn a metabolic inhibiting drug into promising COVID-19 treatment

Engineering hairy cellulose nanocrystals to capture chemotherapy drugs

NEJM article distills available data into a compendium about rapid diagnostic tests for COVID-19

N95 respirators can be safely re-used up to 25 times after VHP decontamination

Omicron variant found to be much less sensitive to neutralizing antibodies than Delta

Researchers isolate Omicron variant, leveling the path to vaccine development and vaccine efficacy studies

Broad cross-neutralization antibodies found to be effective against SARS-CoV-2 Omicron variant

Characteristics of initial hospitalization and readmissions among pediatric patients with COVID-19 in the US

Moderna announces initiation of Phase 1 study of its mRNA-1189 EBV vaccine candidate

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News